Comparable stake leader
BlackRock, Inc.
SEC ownership of Indivior Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001625297.
Disclosed value leader
BlackRock, Inc.
Comparable rows
11/50
Latest evidence
02 Nov 2026
- Public ticker
- INDV on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
11 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Nov 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001625297
- Issuer location
- North Chesterfield, VA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Indivior Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
11/50
Latest evidence
02 Nov 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
39 rows are not safely comparable across share classes.
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 14%.
11 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
14%
VANGUARD PORTFOLIO MANAGEMENT LLC
6.6%
MILLENNIUM MANAGEMENT LLC
5.4%
VANGUARD CAPITAL MANAGEMENT LLC
5.4%
Two Seas Capital LP
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
14%
Reported 13D/G
· 31 Dec 2025
|
$1,202,518,637
28,059,478 shares
mixed-class rows
|
— | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Portfolio Management
|
6.6%
Reported 13D/G
· 31 Mar 2026
|
$464,426,439
10,877,716 shares
mixed-class rows
|
— | 30 Jun 2026 |
| MILLENNIUM MANAGEMENT LLC |
13F
13D/G
Company
|
5.4%
Reported 13D/G
· 23 Sep 2026
|
$265,332,603
5,952,157 shares
mixed-class rows
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Capital Management
|
5.4%
Reported 13D/G
· 31 Mar 2026
|
$342,532,485
8,012,207 shares
mixed-class rows
|
— | 30 Jun 2026 |
| Two Seas Capital LP |
13D/G
13F
Company
|
5%
Reported 13D/G
· 23 Dec 2025
|
$203,438,218
6,211,854 shares
|
-$27,837,500 | 23 Dec 2025 |
| FULLER & THALER ASSET MANAGEMENT, INC. |
13F
13D/G
Company
|
3.7%
Reported 13D/G
· 31 Mar 2026
|
$189,386,924
4,615,816 shares
|
— | 30 Jun 2026 |
| MORGAN STANLEY |
13F
13D/G
Company
|
3.7%
Reported 13D/G
· 31 Mar 2025
|
$180,107,613
4,272,543 shares
mixed-class rows
|
— | 30 Jun 2026 |
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
3.7%
Reported 13D/G
· 10 Nov 2025
|
$111,255,547
4,614,498 shares
|
-$143,518,681 | 10 Nov 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,517,648.
Buys
$311,563
Insiders: 7
Sells
$2,829,211
Insiders: 2
Net
-$2,517,648
Shares: -64,322
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 8,850
Shares: 73,172
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 1,500 | 0 | $53,535 | $0 | +$53,535 |
| 3-6 | 1,500 | 73,172 | $54,420 | $2,829,211 | -$2,774,791 |
| 6-9 | 979 | 0 | $31,211 | $0 | +$31,211 |
| 9-12 | 4,871 | 0 | $172,397 | $0 | +$172,397 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to Indivior Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Jack A. Khattar
Net 12M change
-$2.52M
Full value: -$2,517,649 · USD · 12-month changeLatest report
02 Nov 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jack A. Khattar | Chief Executive Officer, Director | $122,375,946 | Median | 02 Nov 2026 | ||
| Joseph Ciaffoni | Chief Executive Officer, Director | $24,089,258 | Mixed | 22 Jun 2026 | ||
| Ryan Preblick | Chief Financial Officer | $10,735,112 | -$1,357,200 | -11% | Filing P/S | 08 Jun 2026 |
| Christian Heidbreder | Chief Scientific Officer | $8,612,124 | -$1,472,011 | -15% | Filing P/S | 10 Jul 2026 |
| Jeffrey W. Burris | Chief Legal Officer | $2,357,948 | Market | 03 Mar 2026 | ||
| Georges Gemayel | Director | $1,506,022 | Median | 02 Nov 2026 | ||
| Carrolee Barlow | Director | $1,493,224 | Median | 02 Nov 2026 | ||
| Frank Mottola | SVP, Chief Tech. Ops. Officer | $1,079,049 | Median | 02 Nov 2026 | ||
| Patrick A. Barry | Chief Commercial Officer | $1,066,920 | Mixed | 10 Feb 2026 | ||
| Padmanabh P. Bhatt | SVP of IP, CSO | $1,028,966 | Median | 02 Nov 2026 | ||
| David E. Wheadon | Director | $993,575 | +$62,680 | +6.7% | Mixed | 13 May 2026 |
| Woodrow D. Anderson | Chief Accounting Officer | $986,400 | +$107,955 | +12% | Filing P/S | 27 Aug 2026 |
| Daniel A. Ninivaggi | Director | $876,818 | +$27,429 | +3.2% | Mixed | 13 May 2026 |
| Mark Stejbach | Director | $874,365 | +$27,429 | +3.2% | Mixed | 13 May 2026 |
| Jonathan Rubin | SVP, Chief Medical Officer | $771,814 | Median | 02 Nov 2026 | ||
| Juliet Thompson | Director | $605,183 | Mixed | 12 May 2026 | ||
| Keith Humphreys | Director | $517,834 | +$27,429 | +5.6% | Mixed | 13 May 2026 |
| Timothy C. Dec | SVP, Chief Financial Officer | $504,015 | Median | 02 Nov 2026 | ||
| Barbara Ryan | Director | $395,170 | +$28,687 | +7.8% | Mixed | 13 May 2026 |
| Stuart A. Kingsley | Director | $390,586 | +$29,953 | +8.3% | Mixed | 13 May 2026 |
Recent insider transactions for Indivior Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Frank Mottola | INDV | Common Stock | Other | 30,099 | 30,099 | 02 Nov 2026 | Direct | |||
| Frank Mottola | INDV | Restricted Stock Units | Other | 185,810 | 154,010 | 02 Nov 2026 | Direct | |||
| Frank Mottola | INDV | Employee Stock Option (right to buy) | Other | 245,643 | 46,203 | 02 Nov 2026 | Direct | |||
| William Todd Horich | INDV | Restricted Stock Units | Other | 190,391 | 154,010 | 02 Nov 2026 | Direct | |||
| William Todd Horich | INDV | Employee Stock Option (right to buy) | Other | 185,579 | 38,502 | 02 Nov 2026 | Direct | |||
| Timothy C. Dec | INDV | Common Stock | Other | 14,059 | 14,059 | 02 Nov 2026 | Direct | |||
| Timothy C. Dec | INDV | Restricted Stock Units | Other | 139,953 | 107,807 | 02 Nov 2026 | Direct | |||
| Timothy C. Dec | INDV | Employee Stock Option (right to buy) | Other | 334,970 | 130,908 | 02 Nov 2026 | Direct | |||
| Carrolee Barlow | INDV | Common Stock | Other | 41,652 | 41,652 | 02 Nov 2026 | Direct | |||
| Carrolee Barlow | INDV | Director Stock Option (right to buy) | Other | 112,384 | 19,138 | 02 Nov 2026 | Direct | |||
| Carrolee Barlow | INDV | Restricted Stock Units | Other | 4,603 | 4,603 | 02 Nov 2026 | Direct | |||
| Padmanabh P. Bhatt | INDV | Common Stock | Other | 28,702 | 28,702 | 02 Nov 2026 | Direct | |||
| Padmanabh P. Bhatt | INDV | Restricted Stock Units | Other | 183,999 | 154,010 | 02 Nov 2026 | Direct | |||
| Padmanabh P. Bhatt | INDV | Employee Stock Option (right to buy) | Other | 82,394 | 30,802 | 02 Nov 2026 | Direct | |||
| Bethany Sensenig | INDV | Director Stock Option (right to buy) | Other | 68,807 | 37,198 | 02 Nov 2026 | Direct | |||
| Bethany Sensenig | INDV | Restricted Stock Units | Other | 4,603 | 4,603 | 02 Nov 2026 | Direct | |||
| Georges Gemayel | INDV | Common Stock | Other | 42,009 | 42,009 | 02 Nov 2026 | Direct | |||
| Georges Gemayel | INDV | Director Stock Option (right to buy) | Other | 119,215 | 19,138 | 02 Nov 2026 | Direct | |||
| Georges Gemayel | INDV | Restricted Stock Units | Other | 4,603 | 4,603 | 02 Nov 2026 | Direct | |||
| Jack A. Khattar | INDV | Common Stock | Other | 1,475,569 | 1,475,569 | 02 Nov 2026 | By the KBT Trust | |||
| Jack A. Khattar | INDV | Common Stock | Other | 1,937,986 | 1,937,986 | 02 Nov 2026 | Direct | |||
| Jack A. Khattar | INDV | Restricted Stock Units | Other | 1,114,695 | 616,040 | 02 Nov 2026 | Direct | |||
| Jack A. Khattar | INDV | Employee Stock Option (right to buy) | Other | 3,552,270 | 526,113 | 02 Nov 2026 | Direct | |||
| Jonathan Rubin | INDV | Common Stock | Other | 21,529 | 21,529 | 02 Nov 2026 | Direct | |||
| Jonathan Rubin | INDV | Restricted Stock Units | Other | 134,178 | 107,807 | 02 Nov 2026 | Direct | |||
| Jonathan Rubin | INDV | Employee Stock Option (right to buy) | Other | 113,196 | 38,502 | 02 Nov 2026 | Direct | |||
| Woodrow D. Anderson | INDV | Common Stock | Purchase | 5.74% | $53,535 | $35.69 | 1,500 | 27,638 | 27 Aug 2026 | Direct |
| Woodrow D. Anderson | INDV | Common Stock | Purchase | 6.09% | $54,420 | $36.28 | 1,500 | 26,138 | 05 Aug 2026 | Direct |
| Christian Heidbreder | INDV | Common Stock | Sale | -8.15% | -$764,628 | $41.14 | -18,586 | 209,337 | 10 Jul 2026 | Direct |
| Joseph Ciaffoni | INDV | Common Stock | Tax liability | -43.7% | -612,549 | 790,330 | 22 Jun 2026 | Direct | ||
| Joseph Ciaffoni | INDV | Common Stock | Options Exercise | 931.7% | 1,266,903 | 1,402,879 | 22 Jun 2026 | Direct | ||
| Joseph Ciaffoni | INDV | Performance Stock Units | Options Exercise | -100% | -1,266,903 | 0 | 22 Jun 2026 | Direct | ||
| Christian Heidbreder | INDV | Common Stock | Sale | -7.54% | -$707,383 | $38.06 | -18,586 | 227,923 | 11 Jun 2026 | Direct |
| Ryan Preblick | INDV | Common Stock | Sale | -11.2% | -$1,357,200 | $37.70 | -36,000 | 284,751 | 08 Jun 2026 | Direct |
| Juliet Thompson | INDV | Common Stock | Award | 101% | 6,518 | 12,973 | 13 May 2026 | Direct | ||
| Keith Humphreys | INDV | Common Stock | Award | 68.4% | 6,518 | 16,042 | 13 May 2026 | Direct | ||
| Stuart A. Kingsley | INDV | Common Stock | Award | 116.8% | 6,518 | 12,100 | 13 May 2026 | Direct | ||
| Daniel A. Ninivaggi | INDV | Common Stock | Award | 31.6% | 6,518 | 27,163 | 13 May 2026 | Direct | ||
| Barbara Ryan | INDV | Common Stock | Award | 113.9% | 6,518 | 12,242 | 13 May 2026 | Direct | ||
| Mark Stejbach | INDV | Common Stock | Award | 31.7% | 6,518 | 27,087 | 13 May 2026 | Direct | ||
| David E. Wheadon | INDV | Common Stock | Award | 51.2% | 10,430 | 30,780 | 13 May 2026 | Direct | ||
| Juliet Thompson | INDV | Common Stock | Tax liability | -14.8% | -1,117 | 6,455 | 12 May 2026 | Direct | ||
| Ryan Preblick | INDV | Common Stock | Tax liability | -0.88% | -2,843 | 320,751 | 14 Mar 2026 | Direct | ||
| Ryan Preblick | INDV | Common Stock | Options Exercise | 1.99% | 6,302 | 323,594 | 14 Mar 2026 | Direct | ||
| Ryan Preblick | INDV | Restricted Stock Units | Options Exercise | -100% | -6,302 | 0 | 14 Mar 2026 | Direct | ||
| Barbara Ryan | INDV | Common Stock | Purchase | 0.14% | $249 | $31.08 | 8 | 5,724 | 13 Mar 2026 | Direct |
| Barbara Ryan | INDV | Common Stock | Purchase | 0.55% | $1,009 | $32.56 | 31 | 5,716 | 09 Mar 2026 | Direct |
| Stuart A. Kingsley | INDV | Common Stock | Purchase | 20.2% | $29,953 | $31.86 | 940 | 5,582 | 06 Mar 2026 | Direct |
| Woodrow D. Anderson | INDV | Common Stock | Tax liability | -33.9% | -10,965 | 21,374 | 03 Mar 2026 | Direct | ||
| Woodrow D. Anderson | INDV | Common Stock | Options Exercise | 454.6% | 24,310 | 29,657 | 03 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.